SCHEMBL93504

SCHEMBL93504

O=P(OCl)(OCl)OCCBr

nearest known ligand 0.42

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.42
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2141473 0.83 ALDH1A1 (0.50) ALDH1A1CYP3A4
SCHEMBL10597988 0.81 CYP3A4 (0.38) ALDH1A1CYP3A4
SCHEMBL8463495 0.81 CYP3A4 (0.38) ALDH1A1CYP3A4
SCHEMBL11248848 0.80 ALDH1A1 (0.48) ALDH1A1CYP3A4
SCHEMBL5851894 0.80 CYP3A4 (0.41) ALDH1A1CYP3A4
SCHEMBL9555902 0.80 ALDH1A1 (0.31) ALDH1A1
SCHEMBL10627755 0.77 ALDH1A1 (0.75) ALDH1A1CYP3A4
SCHEMBL11547470 0.76 ALDH1A1 (0.74) ALDH1A1CYP3A4
SCHEMBL17180840 0.75
SCHEMBL10611831 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020025848-A1 ZWITTERIONIC COMPOUNDS OF 2-PHOSPHOCHOLINE CARBOXYLIC ACIDS AND THEIR USE AS CYTOTOXIC AGENTS UNIVERSIDAD DE ALICANTE (ES) 2020-02-06 WO claimed
US-20170210775-A1 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS JINA PHARMACEUTICALS, INC. 2017-07-27 US claimed
US-9637515-B2 Guggulphospholipid methods and compositions JINA PHARMACEUTICALS, INC. (US) 2017-05-02 US claimed
EP-2088865-B1 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS JINA PHARMACEUTICALS INC (US) 2015-10-21 EP claimed
US-20100151002-A1 Guggulphospholipid Methods and Compositions JINA PHARMACEUTICALS, INC. (US) 2010-06-17 US claimed
EP-2088865-A2 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS Jina Pharmaceuticals Inc. (US) 2009-08-19 EP claimed
US-20090202816-A1 STABILIZED SILICA COLLOID FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2009-08-13 US claimed
WO-2008058156-A9 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS JINA PHARMACEUTICALS INC (US) 2008-12-04 WO claimed
WO-2008058156-A2 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS JINA PHARMACEUTICALS INC. (US) 2008-05-15 WO claimed
WO-2007146680-A1 STABILIZED SILICA COLLOID FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION , INC. (US) 2007-12-21 WO claimed
JP-58164596-A None JP disclosed
JP-62289588-A None JP disclosed
CN-118019547-A Thermostable lipid nanoparticles and methods of use thereof 默沙东有限责任公司 2024-05-10 CN disclosed
WO-2020025848-A1 ZWITTERIONIC COMPOUNDS OF 2-PHOSPHOCHOLINE CARBOXYLIC ACIDS AND THEIR USE AS CYTOTOXIC AGENTS UNIVERSIDAD DE ALICANTE (ES) 2020-02-06 WO disclosed
US-20170210775-A1 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS JINA PHARMACEUTICALS, INC. 2017-07-27 US disclosed
EP-0089635-A2 Phospholipid derivatives, process for preparation thereof and pharmaceutical composition of the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1983-09-28 EP disclosed
EP-0071892-A2 Phospholipid derivatives, process for preparation thereof and pharmaceutical composition of the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1983-02-16 EP disclosed
EP-0070433-A1 Phospholipid derivatives, processes for preparation thereof and pharmaceutical composition of the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1983-01-26 EP disclosed
US-4156663-A 260/857 R KANEBO, LTD. (JP) 1979-05-29 US disclosed
US-4072658-A FLAME RETARDANTS KANEBO, LTD. (JA) 1978-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100151002-A1 Guggulphospholipid Methods and Compositions SGMS2, SGMS1, PLA2G5 ALDH1A1 4045/4885CYP3A4 1285/4885
US-20170210775-A1 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS SGMS1, SGMS2, GGPS1 ALDH1A1 3991/4885CYP3A4 764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.